Chapter 1. Executive Summary
Chapter 2. Scope Of The Study
2.1. Market Definition
2.2. Scope Of The Study
2.2.1. Objectives of Report
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat Of New Entrants
4.2.2. Bargaining Power Of Buyers
4.2.3. Bargaining Power Of Suppliers
4.2.4. Threat Of Substitutes
4.2.5. Industry Rivalry
4.3. Impact of COVID-19 on Breast Cancer Liquid Biopsy Market
4.3.1. Impact on Market Size
4.3.2. End User Trend, Preferences and Budget Impact
4.3.3. Regulatory Framework/Government Policies
4.3.4. Key Players Strategy to Tackle Negative Impact
4.3.5. Opportunity Window
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DRO Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
Chapter 6. Global Breast Cancer Liquid Biopsy Market, By Circulating Biomarker
6.1. Introduction
6.2. Circulating Tumor Cells
6.3. Cell-free DNA
6.3. Extracellular Vesicles
6.4. Others
Chapter 7. Global Breast Cancer Liquid Biopsy Market, By End User
7.1. Introduction
7.2. Reference Laboratories
7.3. Hospitals and Physician Laboratories
Chapter 8. Global Breast Cancer Liquid Biopsy Market, By Region
8.1. Introduction
8.2. North America
8.2.1. Introduction
8.2.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.3. Market Size and Forecast, By Country, 2020 - 2028
8.2.4. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.2.5. Market Size and Forecast, By End User, 2020 - 2028
8.2.6. US
8.2.6.1. Introduction
8.2.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.6.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.2.6.4. Market Size and Forecast, By End User, 2020 - 2028
8.2.7. Canada
8.2.7.1. Introduction
8.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.7.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.2.7.4. Market Size and Forecast, By End User, 2020 - 2028
8.3. Europe
8.3.1. Introduction
8.3.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.3. Market Size and Forecast, By Country, 2020 - 2028
8.3.4. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.3.5. Market Size and Forecast, By End User, 2020 - 2028
8.3.6. Germany
8.3.6.1. Introduction
8.3.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.6.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.3.6.4. Market Size and Forecast, By End User, 2020 - 2028
8.3.7. France
8.3.7.1. Introduction
8.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.7.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.3.7.4. Market Size and Forecast, By End User, 2020 - 2028
8.3.8. UK
8.3.8.1. Introduction
8.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.8.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.3.8.4. Market Size and Forecast, By End User, 2020 - 2028
8.3.9. Italy
8.3.9.1. Introduction
8.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.9.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.3.9.4. Market Size and Forecast, By End User, 2020 - 2028
8.3.10. Rest Of Europe
8.3.10.1. Introduction
8.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.10.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.3.10.4. Market Size and Forecast, By End User, 2020 - 2028
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.3. Market Size and Forecast, By Country, 2020 - 2028
8.4.4. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.4.5. Market Size and Forecast, By End User, 2020 - 2028
8.4.6. China
8.4.6.1. Introduction
8.4.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.6.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.4.6.4. Market Size and Forecast, By End User, 2020 - 2028
8.4.7. India
8.4.7.1. Introduction
8.4.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.7.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.4.7.4. Market Size and Forecast, By End User, 2020 - 2028
8.4.8. Japan
8.4.8.1. Introduction
8.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.8.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.4.8.4. Market Size and Forecast, By End User, 2020 - 2028
8.4.9. South Korea
8.4.9.1. Introduction
8.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.9.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.4.9.4. Market Size and Forecast, By End User, 2020 - 2028
8.4.10. Rest Of Asia-Pacific
8.4.10.1. Introduction
8.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.10.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.4.10.4. Market Size and Forecast, By End User, 2020 - 2028
8.5. Rest Of The World (RoW)
8.5.1. Introduction
8.5.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.5.4. Market Size and Forecast, By End User, 2020 - 2028
8.5.5. Market Size and Forecast, By Region, 2020 - 2028
8.5.6. South America
8.5.6.1. Introduction
8.5.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.6.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.5.6.4. Market Size and Forecast, By End User, 2020 - 2028
8.5.7. Middle East and Africa
8.5.7.1. Introduction
8.5.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.7.3. Market Size and Forecast, By Circulating Biomarker, 2020 - 2028
8.5.7.4. Market Size and Forecast, By End User, 2020 - 2028
Chapter 9. Competitive Landscape
9.1. Introduction
9.2. Vendor Share Analysis, 2020/Key Players Positioning, 2020
Chapter 10. Company Profiles
10.1. QIAGEN N.V
10.1.1. Business Overview
10.1.2. Financial Analysis
10.1.3. Product Portfolio
10.1.4. Recent Development and Strategies Adopted
10.1.5. SWOT Analysis
10.2. Roche Diagnostics
10.2.1. Business Overview
10.2.2. Financial Analysis
10.2.3. Product Portfolio
10.2.4. Recent Development and Strategies Adopted
10.2.5. SWOT Analysis
10.3. Bio-Rad Laboratories
10.3.1. Business Overview
10.3.2. Financial Analysis
10.3.3. Product Portfolio
10.3.4. Recent Development and Strategies Adopted
10.3.5. SWOT Analysis
10.4. Myriad Genetics
10.4.1. Business Overview
10.4.2. Financial Analysis
10.4.3. Product Portfolio
10.4.4. Recent Development and Strategies Adopted
10.4.5. SWOT Analysis
10.5. Menarini Silicon Biosystems
10.5.1. Business Overview
10.5.2. Financial Analysis
10.5.3. Product Portfolio
10.5.4. Recent Development and Strategies Adopted
10.5.5. SWOT Analysis
10.6. Illumina
10.6.1. Business Overview
10.6.2. Financial Analysis
10.6.3. Product Portfolio
10.6.4. Recent Development and Strategies Adopted
10.6.5. SWOT Analysis
10.7. Cynvenio Biosystems, Inc
10.7.1. Business Overview
10.7.2. Financial Analysis
10.7.3. Product Portfolio
10.7.4. Recent Development and Strategies Adopted
10.7.5. SWOT Analysis
10.8. Genomic Health, Inc
10.8.1. Business Overview
10.8.2. Financial Analysis
10.8.3. Product Portfolio
10.8.4. Recent Development and Strategies Adopted
10.8.5. SWOT Analysis
10.9. Thermo Fisher Scientific Inc.
10.9.1. Business Overview
10.9.2. Financial Analysis
10.9.3. Product Portfolio
10.9.4. Recent Development and Strategies Adopted
10.9.5. SWOT Analysis
10.10. Fluxion Biosciences, Inc
10.10.1. Business Overview
10.10.2. Financial Analysis
10.10.3. Product Portfolio
10.10.4. Recent Development and Strategies Adopted
10.10.5. SWOT Analysis
Chapter 11. Key Takeaways